Skip to main content
Premium Trial:

Request an Annual Quote

Geospiza Reels in SBIR Grant

NEW YORK (GenomeWeb News) - Geospiza has won a Small Business Innovation Research grant from the National Human Genome Research Institute to fund genomic analysis software development, the company said today.

The Seattle-based company plans to use the Phase I grant to develop software that will be used in detecting rare mutations found in certain cancer types and to help make treatment decisions.

"New sequencing technologies are advancing at a significant pace and the instrument vendors are making tremendous progress in developing a wide range of applications that will change how we examine gene expression and study how variations in DNA sequences cause disease and impact health," Geospiza CSO Todd Smith said in a statement.

"This award will help us conduct important research to develop new methods to support resequencing applications," he added.

Geospiza did not disclose the amount of the grant, but standard Phase I SBIR awards last up to six months and grant as much as $100,000.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.